Blood test may predict kidney decline in diabetes — a large trial investigates

NCT ID NCT04802395

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study is testing whether a diagnostic test called KidneyIntelX can help primary care doctors improve care for people with type 2 diabetes and chronic kidney disease. The test predicts the risk of kidney function worsening. Researchers will see if using this test leads to more referrals to specialists and better use of protective medications. The goal is to slow kidney damage and improve patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KidneyIntelX, a diagnostic test that predicts the risk of kidney function decline in people with type 2 diabetes and chronic kidney disease
What this could lead to
If it works, this test could help doctors identify high-risk patients earlier and guide treatments to slow kidney damage.
What could go wrong
This is a real-world study, not a controlled trial, so results may vary across clinics. The test's impact on long-term outcomes is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mount Sinai Health System

    RECRUITING

    New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.